Effector and central memory poly-functional CD4+ and CD8+ T cells are boosted upon ZOSTAVAX® vaccination

Frontiers in Immunology

Volumn 6, Issue OCT, 2015, Pages

  Sei, Janet J ^a   Cox, Kara S ^a   Dubey, Sheri A ^a   Antonello, Joseph M ^a   Krah, David L ^a   Casimiro, Danilo R ^a   Vora, Kalpit A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Flow cytometry; Memory response; Poly functional T cells; VZV antigens; ZOSTAVAX

Indexed keywords

GAMMA INTERFERON; IMMEDIATE EARLY PROTEIN; INTERLEUKIN 2; TUMOR NECROSIS FACTOR ALPHA; VARICELLA ZOSTER VACCINE;

ADULT; AGED; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOSTIMULATION; MALE; MEMORY CELL; NORMAL HUMAN; OPEN READING FRAME; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; VACCINATION;

EID: 84946574838     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2015.00553     Document Type: Article

References (69)

1. Mueller NH, Gilden DH, Cohrs RJ, Mahalingam R, Nagel MA. Varicella zoster virus infection: clinical features, molecular pathogenesis of disease, and latency. Neurol Clin (2008) 26:675-697,viii. doi: 10.1016/j.ncl.2008.03.011.
2. Hope-Simpson RE. The nature of herpes zoster: a long-term study and a new hypothesis. Proc R Soc Med (1965) 58:9-20.
3. Kumagai T, Chiba Y, Wataya Y, Hanazono H, Chiba S, Nakao T. Development and characteristics of the cellular immune response to infection with varicella-zoster virus. J Infect Dis (1980) 141:7-13. doi:10.1093/infdis/141.1.7.
4. Arvin AM, Koropchak CM, Williams BR, Grumet FC, Foung SK. Early immune response in healthy and immunocompromised subjects with primary varicella-zoster virus infection. J Infect Dis (1986) 154:422-9. doi:10.1093/infdis/154.3.422.
5. Hope-Simpson RE. Postherpetic neuralgia. J R Coll Gen Pract (1975) 25:571-5.
6. Burke BL, Steele RW, Beard OW, Wood JS, Cain TD, Marmer DJ. Immune responses to varicella-zoster in the aged. Arch Intern Med (1982) 142:291-3. doi:10.1001/archinte.1982.00340150091017.
7. Buchbinder SP, Katz MH, Hessol NA, Liu JY, O'Malley PM, Underwood R, et al. Herpes zoster and human immunodeficiency virus infection. J Infect Dis (1992) 166:1153-6. doi:10.1093/infdis/166.5.1153.
8. Kost RG, Straus SE. Postherpetic neuralgia-pathogenesis, treatment, and prevention. N Engl J Med (1996) 335:32-42. doi:10.1056/NEJM199607043350107.
9. Patterson-Bartlett J, Levin MJ, Lang N, Schodel FP, Vessey R, Weinberg A. Phenotypic and functional characterization of ex vivo T cell responses to the live attenuated herpes zoster vaccine. Vaccine (2007) 25:7087-93. doi:10.1016/j.vaccine.2007.07.051.
10. Yawn BP, Saddier P, Wollan PC, St Sauver JL, Kurland MJ, Sy LS. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc (2007) 82:1341-9. doi:10.4065/82.11.1341.
11. Schub D, Janssen E, Leyking S, Sester U, Assmann G, Hennes P, et al. Altered phenotype and functionality of varicella zoster virus-specific cellular immunity in individuals with active infection. J Infect Dis (2015) 211:600-12. doi:10.1093/infdis/jiu500.
12. Miller AE. Selective decline in cellular immune response to varicella-zoster in the elderly. Neurology (1980) 30:582-7. doi:10.1212/WNL.30.6.582.
13. Levin MJ, Oxman MN, Zhang JH, Johnson GR, Stanley H, Hayward AR, et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J Infect Dis (2008) 197:825-35. doi:10.1086/528696.
14. Arvin AM, Sharp M, Smith S, Koropchak CM, Diaz PS, Kinchington P, et al. Equivalent recognition of a varicella-zoster virus immediate early protein (IE62) and glycoprotein I by cytotoxic T lymphocytes of either CD4+ or CD8+ phenotype. J Immunol (1991) 146:257-64.
15. Sadzot-Delvaux C, Arvin AM, Rentier B. Varicella-zoster virus IE63, a virion component expressed during latency and acute infection, elicits humoral and cellular immunity. J Infect Dis (1998) 178(Suppl 1):S43-7. doi:10.1086/514259.
16. Abendroth A, Arvin A. Varicella-zoster virus immune evasion. Immunol Rev (1999) 168:143-56. doi:10.1111/j.1600-065X.1999.tb01289.x.
17. Frey CR, Sharp MA, Min AS, Schmid DS, Loparev V, Arvin AM. Identification of CD8+ T cell epitopes in the immediate early 62 protein (IE62) of varicella-zoster virus, and evaluation of frequency of CD8+ T cell response to IE62, by use of IE62 peptides after varicella vaccination. J Infect Dis (2003) 188:40-52. doi:10.1086/375828.
18. Jones L, Black AP, Malavige GN, Ogg GS. Phenotypic analysis of human CD4+ T cells specific for immediate-early 63 protein of varicella-zoster virus. Eur J Immunol (2007) 37:3393-403. doi:10.1002/eji.200737648.
19. Malavige GN, Jones L, Black AP, Ogg GS. Varicella zoster virus glycoprotein E-specific CD4+ T cells show evidence of recent activation and effector differentiation, consistent with frequent exposure to replicative cycle antigens in healthy immune donors. Clin Exp Immunol (2008) 152:522-31. doi:10.1111/j.1365-2249.2008.03633.x.
20. Kleemann P, Distler E, Wagner EM, Thomas S, Klobuch S, Aue S, et al. Varicella-zoster virus glycoproteins B and E are major targets of CD4+ and CD8+ T cells reconstituting during zoster after allogeneic transplantation. Haematologica (2012) 97:874-82. doi:10.3324/haematol.2011.052597.
21. Asanuma H, Sharp M, Maecker HT, Maino VC, Arvin AM. Frequencies of memory T cells specific for varicella-zoster virus, herpes simplex virus, and cytomegalovirus by intracellular detection of cytokine expression. J Infect Dis (2000) 181:859-66. doi:10.1086/315347.
22. Jones L, Black AP, Malavige GN, Ogg GS. Persistent high frequencies of varicella-zoster virus ORF4 protein-specific CD4+ T cells after primary infection. J Virol (2006) 80:9772-8. doi:10.1128/JVI.00564-06.
23. Malavige GN, Jones L, Black AP, Ogg GS. Rapid effector function of varicella-zoster virus glycoprotein I-specific CD4+ T cells many decades after primary infection. J Infect Dis (2007) 195:660-4. doi:10.1086/511274.
24. Schmader KE, Levin MJ, Gnann JW Jr, Mcneil SA, Vesikari T, Betts RF, et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis (2012) 54:922-8. doi:10.1093/cid/cir970.
25. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med (2005) 352:2271-84. doi:10.1056/NEJMoa051016.
26. Vermeulen JN, Lange JM, Tyring SK, Peters PH, Nunez M, Poland G, et al. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults >/= 60 years of age. Vaccine (2012) 30:904-10. doi:10.1016/j.vaccine.2011.11.096.
27. Gilbert PB, Gabriel EE, Miao X, Li X, Su SC, Parrino J, et al. Fold rise in antibody titers by measured by glycoprotein-based enzyme-linked immunosorbent assay is an excellent correlate of protection for a herpes zoster vaccine, demonstrated via the vaccine efficacy curve. J Infect Dis (2014) 210:1573-81. doi:10.1093/infdis/jiu279.
28. Laing KJ, Russell RM, Dong L, Schmid DS, Stern M, Magaret A, et al. Zoster vaccination increases the breadth of CD4+ T cells responsive to varicella zoster virus. J Infect Dis (2015) 212(7):1022-31. doi:10.1093/infdis/jiv164.
29. Gomi Y, Sunamachi H, Mori Y, Nagaike K, Takahashi M, Yamanishi K. Comparison of the complete DNA sequences of the Oka varicella vaccine and its parental virus. J Virol (2002) 76:11447-59. doi:10.1128/JVI.76.22.11447-11459.2002.
30. De Rosa SC, Lu FX, Yu J, Perfetto SP, Falloon J, Moser S, et al. Vaccination in humans generates broad T cell cytokine responses. J Immunol (2004) 173:5372-80. doi:10.4049/jimmunol.173.9.5372.
31. Horton H, Thomas EP, Stucky JA, Frank I, Moodie Z, Huang Y, et al. Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by vaccination. J Immunol Methods (2007) 323:39-54. doi:10.1016/j.jim.2007.03.002.
32. Lovelace P, Maecker HT. Multiparameter intracellular cytokine staining. Methods Mol Biol (2011) 699:165-78. doi:10.1007/978-1-61737-950-5_8.
33. De Rosa SC, Carter DK, Mcelrath MJ. OMIP-014: validated multifunctional characterization of antigen-specific human T cells by intracellular cytokine staining. Cytometry A (2012) 81:1019-21. doi:10.1002/cyto.a.22218.
34. Lelic A, Verschoor CP, Ventresca M, Parsons R, Evelegh C, Bowdish D, et al. The polyfunctionality of human memory CD8+ T cells elicited by acute and chronic virus infections is not influenced by age. PLoS Pathog (2012) 8:e1003076. doi:10.1371/journal.ppat.1003076.
35. Kierstead LS, Dubey S, Meyer B, Tobery TW, Mogg R, Fernandez VR, et al. Enhanced rates and magnitude of immune responses detected against an HIV vaccine: effect of using an optimized process for isolating PBMC. AIDS Res Hum Retroviruses (2007) 23:86-92. doi:10.1089/aid.2006.0129.
36. Roederer M, Nozzi JL, Nason MC. SPICE: exploration and analysis of post-cytometric complex multivariate datasets. Cytometry A (2011) 79:167-74. doi:10.1002/cyto.a.21015.
37. Sylwester AW, Mitchell BL, Edgar JB, Taormina C, Pelte C, Ruchti F, et al. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med (2005) 202:673-85. doi:10.1084/jem.20050882.
38. Jing L, Haas J, Chong TM, Bruckner JJ, Dann GC, Dong L, et al. Cross-presentation and genome-wide screening reveal candidate T cells antigens for a herpes simplex virus type 1 vaccine. J Clin Invest (2012) 122:654-73. doi:10.1172/JCI60556.
39. Abendroth A, Arvin AM, Moffat JF. Varicella-zoster virus. Preface. Curr Top Microbiol Immunol (2010) 342:v-vi. doi:10.1007/82_2010_41.
40. Arvin AM, Kinney-Thomas E, Shriver K, Grose C, Koropchak CM, Scranton E, et al. Immunity to varicella-zoster viral glycoproteins, gp I (gp 90/58) and gp III (gp 118), and to a nonglycosylated protein, p 170. J Immunol (1986) 137:1346-51.
41. Giller RH, Winistorfer S, Grose C. Cellular and humoral immunity to varicella zoster virus glycoproteins in immune and susceptible human subjects. J Infect Dis (1989) 160:919-28. doi:10.1093/infdis/160.6.919.
42. Hayward A, Giller R, Levin M. Phenotype, cytotoxic, and helper functions of T cells from varicella zoster virus stimulated cultures of human lymphocytes. Viral Immunol (1989) 2:175-84. doi:10.1089/vim.1989.2.175.
43. Bergen RE, Sharp M, Sanchez A, Judd AK, Arvin AM. Human T cells recognize multiple epitopes of an immediate early/tegument protein (IE62) and glycoprotein I of varicella zoster virus. Viral Immunol (1991) 4:151-66. doi:10.1089/vim.1991.4.151.
44. Arvin AM, Sharp M, Moir M, Kinchington PR, Sadeghi-Zadeh M, Ruyechan WT, et al. Memory cytotoxic T cell responses to viral tegument and regulatory proteins encoded by open reading frames 4, 10, 29, and 62 of varicella-zoster virus. Viral Immunol (2002) 15:507-16. doi:10.1089/088282402760312377.
45. Malavige GN, Rohanachandra LT, Jones L, Crack L, Perera M, Fernando N, et al. IE63-specific T-cell responses associate with control of subclinical varicella zoster virus reactivation in individuals with malignancies. Br J Cancer (2010) 102:727-30. doi:10.1038/sj.bjc.6605542.
46. Meyer C, Kerns A, Haberthur K, Dewane J, Walker J, Gray W, et al. Attenuation of the adaptive immune response in rhesus macaques infected with simian varicella virus lacking open reading frame 61. J Virol (2013) 87:2151-63. doi:10.1128/JVI.02369-12.
47. Koelle DM, Frank JM, Johnson ML, Kwok WW. Recognition of herpes simplex virus type 2 tegument proteins by CD4 T cells infiltrating human genital herpes lesions. J Virol (1998) 72:7476-83.
48. Hosken N, Mcgowan P, Meier A, Koelle DM, Sleath P, Wagener F, et al. Diversity of the CD8+ T-cell response to herpes simplex virus type 2 proteins among persons with genital herpes. J Virol (2006) 80:5509-15. doi:10.1128/JVI.02659-05.
49. Laing KJ, Magaret AS, Mueller DE, Zhao L, Johnston C, De Rosa SC, et al. Diversity in CD8(+) T cell function and epitope breadth among persons with genital herpes. J Clin Immunol (2010) 30:703-22. doi:10.1007/s10875-010-9441-2.
50. Sadzot-Delvaux C, Kinchington PR, Debrus S, Rentier B, Arvin AM. Recognition of the latency-associated immediate early protein IE63 of varicella-zoster virus by human memory T lymphocytes. J Immunol (1997) 159:2802-6.
51. Cohrs RJ, Hurley MP, Gilden DH. Array analysis of viral gene transcription during lytic infection of cells in tissue culture with varicella-zoster virus. J Virol (2003) 77:11718-32. doi:10.1128/JVI.77.21.11718-11732.2003.
52. Chattopadhyay PK, Yu J, Roederer M. A live-cell assay to detect antigen-specific CD4+ T cells with diverse cytokine profiles. Nat Med (2005) 11:1113-7. doi:10.1038/nm1293.
53. Michie CA, Mclean A, Alcock C, Beverley PC. Lifespan of human lymphocyte subsets defined by CD45 isoforms. Nature (1992) 360:264-5. doi:10.1038/360264a0.
54. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature (1999) 401:708-12. doi:10.1038/44385.
55. Champagne P, Ogg GS, King AS, Knabenhans C, Ellefsen K, Nobile M, et al. Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature (2001) 410:106-11. doi:10.1038/35065118.
56. Hersperger AR, Makedonas G, Betts MR. Flow cytometric detection of perforin upregulation in human CD8 T cells. Cytometry A (2008) 73:1050-7. doi:10.1002/cyto.a.20596.
57. Darrah PA, Patel DT, De Luca PM, Lindsay RW, Davey DF, Flynn BJ, et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med (2007) 13:843-50. doi:10.1038/nm1592.
58. Betts MR, Nason MC, West SM, De Rosa SC, Migueles SA, Abraham J, et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood (2006) 107:4781-9. doi:10.1182/blood-2005-12-4818.
59. Casazza JP, Betts MR, Price DA, Precopio ML, RuffLE, Brenchley JM, et al. Acquisition of direct antiviral effector functions by CMV-specific CD4+ T lymphocytes with cellular maturation. J Exp Med (2006) 203:2865-77. doi:10.1084/jem.20052246.
60. Precopio ML, Betts MR, Parrino J, Price DA, Gostick E, Ambrozak DR, et al. Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses. J Exp Med (2007) 204:1405-16. doi:10.1084/jem.20062363.
61. Miller JD, Van Der Most RG, Akondy RS, Glidewell JT, Albott S, Masopust D, et al. Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity (2008) 28:710-22. doi:10.1016/j.immuni.2008.02.020.
62. Leroux-Roels I, Leroux-Roels G, Clement F, Vandepapeliere P, Vassilev V, Ledent E, et al. A phase 1/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein e subunit vaccine candidate in young and older adults. J Infect Dis (2012) 206:1280-90. doi:10.1093/infdis/jis497.
63. Arvin AM. Cell-mediated immunity to varicella-zoster virus. J Infect Dis (1992) 166(Suppl 1):S35-41. doi:10.1093/infdis/166.Supplement_1.S35.
64. Kannanganat S, Ibegbu C, Chennareddi L, Robinson HL, Amara RR. Multiple-cytokine-producing antiviral CD4 T cells are functionally superior to single-cytokine-producing cells. J Virol (2007) 81:8468-76. doi:10.1128/JVI.00228-07.
65. Bogdan C, Moll H, Solbach W, RollinghoffM. Tumor necrosis factor-alpha in combination with interferon-gamma, but not with interleukin 4 activates murine macrophages for elimination of Leishmania major amastigotes. Eur J Immunol (1990) 20:1131-5. doi:10.1002/eji.1830200528.
66. Liew FY, Li Y, Millott S. Tumor necrosis factor-alpha synergizes with IFN-gamma in mediating killing of Leishmania major through the induction of nitric oxide. J Immunol (1990) 145:4306-10.
67. Morgan DA, Ruscetti FW, Gallo R. Selective in vitro growth of T lymphocytes from normal human bone marrows. Science (1976) 193:1007-8. doi:10.1126/science.181845.
68. Chiu C, Mccausland M, Sidney J, Duh FM, Rouphael N, Mehta A, et al. Broadly reactive human CD8 T cells that recognize an epitope conserved between VZV, HSV and EBV. PLoS Pathog (2014) 10:e1004008. doi:10.1371/journal.ppat.1004008.
69. Cilloniz C, Jackson W, Grose C, Czechowski D, Hay J, Ruyechan WT. The varicella-zoster virus (VZV) ORF9 protein interacts with the IE62 major VZV transactivator. J Virol (2007) 81:761-74. doi:10.1128/JVI.01274-06.